Teladoc Health (TDOC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.12
- Estimate
- -$0.19
- Surprise
- +36.5%
- Revenue (period 2026-09-30)
- $605.1M
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
Teladoc Health (TDOC) reported a narrower loss than forecast — adjusted EPS of -$0.12 against the -$0.19 estimate (a 36.5% beat on a still-unprofitable quarter).
Coverage in the report window
- JP Morgan Maintains Neutral on Teladoc Health, Raises Price Target to $10 — benzinga, 2026-10-30
- Deutsche Bank Adjusts Teladoc Health Price Target to $11 From $10 — fiscal.ai, 2026-10-30
- BofA Securities Adjusts Teladoc Health Price Target — fiscal.ai, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates TDOC Sell at 4.0/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +36.5% surprise compares with a +31.5% four-quarter average. Next scheduled report: 2027-02-24.
What argues against it
- Target reached (-2.5% upside)
- Quality below floor (3.1 < 4.0)
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.13
- Stop
- $7.56
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
TDOC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.55B
- P/E (fwd)
- -15.3
- 52-week range
- $4.40–$9.89
- Off 52-week high
- 17.8%
- RSI (14)
- 42
- Volume vs avg
- 0.40×
- Score today
- 4.0/10